Published in Vaccine Weekly, August 16th, 2006
According to researchers in the United States, "We have shown that vaccination with the recombinant N terminus of Als1p (rAls1p-N) protects mice against disseminated and oropharyngeal candidiasis. We now report that vaccination of mice with a related candidate, rA1s3p-N, induces a broader antibody response than rA1s1p-N and a similar cell-mediated immune response."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly